MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at the INNODIA Annual Meeting in Leuven, Belgium on April 11, 2024. SAB will be featured as a key partner at the upcoming global T1D meeting.
INNODIA accelerates the development of disease modifying therapies for T1D by supporting medicine developers with the following services: teams of leading experts to advise medicine developers; a best-in-class network of accredited clinical trial sites in Europe; a gateway to top notch professionals and research labs working on T1D; and access to a qualified community of people and families living with T1D.
INNODIA Managing Director Manuela Battaglia, Ph.D, said of the partnership, "SAB-142 is an exciting therapy in development, and we are optimistic about partnership opportunities for upcoming clinical trials with this novel agent. Our partnership will provide SAB – as with all our partners – access to our network of clinical trial sites and T1D experts as we work together to accelerate this important therapy."
"INNODIA has been an exceptional partner as we move our SAB-142 development plan forward," noted Dr. Kropotova. "There is urgent and unmet global need for disease-modifying autoimmune therapies that address the underlying cause of disease, and we look forward to working with INNODIA's network of clinicians and scientists as we advance SAB-142 and work to delay the progression of type 1 diabetes."
Dr. Kropotova's presentation will highlight the ...